Adam Roth
Psychiatry · Annapolis, MDNPI 1457550428
Payments from drug & device makers
Across 939 payments — averaging $223.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$123K
- Alkermes, Inc.$42K
- Sunovion Pharmaceuticals Inc.$21K
- Neurocrine Biosciences, Inc.$17K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Lundbeck LLC$2K
- plus $3K from 14 others
What the payments were for
- Consulting fees$14,0457%
- Speaking & faculty fees$175,12484%
- Travel & lodging$8,4834%
- Food & beverage$11,7736%
- Education$2940%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 351 | $122,894 |
| Alkermes, Inc. | 63 | $42,230 |
| Sunovion Pharmaceuticals Inc. | 128 | $20,827 |
| Neurocrine Biosciences, Inc. | 43 | $16,507 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 69 | $2,970 |
| Lundbeck LLC | 173 | $1,573 |
| Jazz Pharmaceuticals Inc. | 15 | $1,010 |
| Otsuka America Pharmaceutical, Inc. | 30 | $516 |
| Vanda Pharmaceuticals Inc. | 21 | $477 |
| Avanir Pharmaceuticals, Inc. | 12 | $204 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $146 |
| Axsome Therapeutics, Inc. | 6 | $97 |
| Alfasigma USA, Inc. | 3 | $63 |
| Teva Pharmaceuticals USA, Inc. | 3 | $58 |
| Acadia Pharmaceuticals Inc | 2 | $44 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $33 |
| Shire North American Group Inc | 2 | $27 |
| Eisai Inc. | 1 | $17 |
| OWP Pharmaceuticals, Inc. | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$209,718 in reported general payments places this provider in the 95th percentile of 851 psychiatry providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 34 | $162,562 |
| VraylarCariprazine Hcl | 50 | $69,174 |
| RexultiBrexpiprazole | 34 | $56,386 |
| TrintellixVortioxetine Hydrobromide | 22 | $19,024 |
| SunosiSolriamfetol Hcl | 17 | $17,731 |
| Duloxetine Hcl | 123 | $6,451 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $5,561 |
| Atomoxetine Hcl | 33 | $5,109 |
| Aripiprazole | 42 | $4,990 |
| Olanzapine | 111 | $4,877 |
| Armodafinil | 27 | $4,815 |
| Vilazodone Hcl | 18 | $3,181 |
| Bupropion XlBupropion Hcl | 43 | $2,333 |
| Mirtazapine | 35 | $2,292 |
| Trazodone Hcl | 30 | $1,975 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $44 | $162,56234 claims |
| AbbVieVraylar | $122,894 | $69,17450 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $516 | $56,38634 claims |
| Axsome Therapeutics, Inc.Sunosi, Auvelity | $97 | $23,29228 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $146 | $19,02422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 851 psychiatry providers in Maryland.
Other psychiatry in Annapolis
- Elia Acevedo DiazGaithersburg$15.8M
- Akira SawaBaltimore$5.1M
- John VaethBaltimore$2.1M
- Paul RosenbergBaltimore$1.9M
- Scott AaronsonBaltimore$1.3M
- Karen AndersonBaltimore$1.1M
- Constantine LyketsosBaltimore$1.1M
- Alan JonasBaltimore$1.1M
- Sarah HertsBaltimore$1M
- Robert LehmanBaltimore$947K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.